Toward a predictive understanding of molecular recognition

Immunological Reviews

Volumn 163, Issue , 1998, Pages 251-266

  Weng, Zhiping ^a   DeLisi, Charles ^a  

^a Boston University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMER; T LYMPHOCYTE RECEPTOR;

ANTIGEN RECOGNITION; APOPTOSIS; CELL MEMBRANE; DIMERIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN TERTIARY STRUCTURE; RECEPTOR AFFINITY; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIGEN PRESENTATION; HISTOCOMPATIBILITY ANTIGENS; HLA ANTIGENS; HUMANS; LIGANDS; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 0031868557     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1998.tb01201.x     Document Type: Review

References (109)

1. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987;329:506-512.
2. Stern LJ, Wiley DC. Antigenic peptide binding by class I and class II histocompatibility proteins. Structure 1994;2:245-251.
3. Rammensee HG. Chemistry of peptides associated with MHC class I and class II molecules. Curr Opin Immunol 1995;7:85-96.
4. Jones EY. MHC class I and class II structures. Curr Opin Immunol 1997;9:75-79.
5. Bentley GA, Boulot G, Karjalainen K, Mariuzza RA. Crystal structure of the β chain of a T cell antigen receptor. Science 1995;267:1984-1987.
6. Fields BA, et al. Crystal structure of the Vα domain of a T cell antigen receptor. Science 1995;270:1821-1824.
7. Housset D, Mazza G, Gregoire C, Piras C, Malissen B, Fontecilla-Camps JC. The three-dimensional structure of a T-cell antigen receptor Vα Vβ heterodimer reveals a novel arrangement of the Vβ domain. EMBO J 1997;16:4205-4216.
8. Garboczi DN, Ghosh P, Utz U, Fan QR, Biddison WE, Wiley DC. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 1996;384:134-141.
9. Garboczi DN, et al. Assembly, specific binding, and crystallization of a human TCR-αβ with an antigenic Tax peptide from human T lymphotropic virus type 1 and the class I MHC molecule HLA-A2. J Immunol 1996;157:5403-5410.
10. Garcia KC, et al. An αβ cell receptor structure at 2.5 Å and its orientation in the TCR-MHC complex. Science 1996;274:209-219.
11. Garcia KC, et al. Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen. Science 1998;279:1166-1172.
12. Wu H, Kwong PD, Hendrickson WA. Dimeric association and segmental variability in the structure of human CD4. Nature 1997;387:527-530.
13. Gao GF, et al. Crystal structure of the complex between human CD8α(α) and HLA-A2. Nature 1997;387:630-634.
14. Hatada MH, et al. Molecular basis for interaction of the protein tyrosine kinase ZAP-70 with the T-cell receptor. Nature 1995;377:32-38.
15. Boniface JJ, Davis MM. T-cell recognition of antigen. A process controlled by transient intermolecular interactions. Ann N Y Acad Sci 1995;766:62-69.
16. Margulies DH. Interactions of TCRs with MHC-peptide complexes: a quantitative basis for mechanistic models. Curr Opin Immunol 1997;9:390-395.
17. Davis MM, Chien Y. Topology and affinity of T-cell receptor mediated recognition of peptide-MHC complexes. Curr Opin Immunol 1993;5:45-49.
18. Fantl WJ, Johnson DE, Williams LT. Signalling by receptor tyrosine kinases. Annu Rev Biochem 1993;62:453-481.
19. Weiss A, Littman DR. Signal transduction by lymphocyte antigen receptors. Cell 1994;76:263-274.
20. Cantrell D. T cell antigen receptor signal transduction pathways. Annu Rev Immunol 1996;14:259-274.
21. Alberola-Ila J, Takaki S, Kerner JD, Perlmutter RM. Differential signaling by lymphocyte antigen receptors. Annu Rev Immunol 1997;15:125-154.
22. Berridge MJ. Lymphocyte activation in health and disease. Crit Rev Immunol 1997;17:155-178.
23. Bowers K, Pitcher C, Marsh M. CD4: a coreceptor in the immune response and HIV infection. Int J Biochem Cell Biol 1997;29:871-875.
24. Chambers CA, Allison JP. Co-stimulation in T cell responses. Curr Opin Immunol 1997;9:396-404.
25. Cheng AM, Chan AC. Protein tyrosine kinases in thymocyte development. Curr Opin Immunol 1997;9:528-533.
26. Croft M, Dubey C. Accessory molecule and costimulation requirements for CD4 T cell response. Crit Rev Immunol 1997;17:89-118.
27. Qian D, Weiss A. T cell antigen receptor signal transduction. Curr Opin Cell Biol 1997;9:205-212.
28. Shores EW, Love PE. TCR ζ chain in T cell development and selection. Curr Opin Immunol 1997;9:380-389.
29. Green JM, et al. T cell costimulation through the CD28 receptor. Proc Assoc Am Physicians 1995;107:41-46.
30. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996;14:233-258.
31. Segal DM, Taurog JD, Metzger H. Dimeric immunoglobulin E serves as a unit signal for mast cell degranulation. Proc Natl Acad Sci USA 1977;74:2993-2997.
32. DeLisi C, Siraganian RP. Receptor cross-linking and histamine release. II. Interpretation and analysis of anomalous dose response patterns. J Immunol 1979;122:2293-2299.
33. DeLisi C, Siraganian RP. Receptor cross-linking and histamine release. I. The quantitative dependence of basophil degranulation on the number of receptor doublets. J Immunol 1979;122:2286-2292.
34. Chabay R, DeLisi C, Hook WA, Siraganian RP. Receptor cross-linking and histamine release in basophils. J Biol Chem 1980;255:4628-4635.
35. Dembo M, Goldstein B. A model of cell activation and desensitization by surface immunoglobulin: the case of histamine release from human basophils. Cell 1980;22:59-67.
36. Kagey-Sobotka A, Dembo M, Goldstein B, Metzger H, Lichtenstein LM. Qualitative characteristics of histamine release from human basophils by covalently cross-linked IgE. J Immunol 1981;127:2285-2291.
37. Dembo M, Kagey-Sobotka A, Lichtenstein LM, Goldstein B. Kinetic analysis of histamine release due to covalently linked IgE dimers. Mol Immunol 1982;19:421-434.
38. Perelson AS, DeLisi C, Siraganian RP. A method for determining whether the descending limb of a biphasic histamine release curve reflects insufficient cross-linking. Mol Immunol 1982;19:13-20.
39. Korystov YN. Cross-linking of cell surface receptors as a trigger of cell apoptosis and proliferation. Scanning Microsc 1995;9:757-762.
40. + thymocytes are preferentially induced to die following CD45 cross-linking, through a novel apoptotic pathway. J Immunol 1997;159:4762-4771.
41. Anderson G, Moore NC, Owen JJ, Jenkinson EJ. Cellular interactions in thymocyte development. Annu Rev Immunol 1996;14:73-99.
42. Eigen M. In: Mintz SL, Widmayer SM, eds. Quantum statistical mechanics in the natural sciences. New York: Plenum; 1974.
43. Berg HC, Purcell EM. Physics of chemoreception. Biophys J 1977;20:193-219.
44. DeLisi C, Wiegel FW. Effect of nonspecific forces and finite receptor number on rate constants of ligand-cell bound-receptor interactions. Proc Natl Acad Sci USA 1981;78:5569-5572.
45. Vajda S, Weng Z, Rosenfeld R, DeLisi C. Effect of conformational flexibility and solvation on receptor-ligand binding free energies. Biochemistry 1994;33:13977-13988.
46. DeLisi C. The biophysics of ligand-receptor interactions. Q Rev Biophys 1980;13:201-230.
47. Adamson AW. Physical chemistry of surfaces. New York: J. Wiley; 1982.
48. Nicholls A, Sharp KA, Honig B. Protein folding and association - insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins 1991;11:281-296.
49. Horton N, Lewis M. Calculation of the free energy of association for protein complexes. Protein Sci 1992;1:169-181.
50. Krystek S, Stouch T, Novotny J. Affinity and specificity of serine endopeptidase - protein inhibitor interactions. J Mol Biol 1993;234:661-679.
51. Jackson RM, Sternberg MJE. A continuum model for protein-protein interactions: Application to the docking problem. J Mol Biol 1995;250:258-275.
52. Nauchitel V, Villaverde MC, Sussman F. Solvent accessibility as a predictive tool for the free energy of inhibitor binding to the HIV-1 protease. Protein Sci 1995;4:1356-1364.
53. Weng Z, Vajda S, DeLisi C. Prediction of protein complexes using empirical free energy functions. Protein Sci 1996;5:614-626.
54. Novotny J, Bruccoleri RE, Davis M, Sharp KA. Empirical free energy calculations: a blind test and further improvements to the method. J Mol Biol 1997;268:401-411.
55. Froloff N, Windemuth A, Honig B. On the calculation of binding free energies using continuum methods: application to MHC class I protein-peptide interactions. Protein Sci 1997;6:1293-1301.
56. Novotny J, Bruccoleri RE, Saul FA. On the attribution of binding energy in the antigen-antibody complexes McPC 603, D1.3 and HyHEL-5. Biochemistry 1989;28:4735-4749.
57. Zhang C, Cornette JL, DeLisi C. Consistency in structural energetics of protein folding and peptide recognition. Protein Sci 1997;6:1057-1064.
58. Zhang C, Vasmatzis G, Cornette JL, DeLisi C. Determination of atomic desolvation energies from the structures of crystallized proteins. J Mol Biol 1997;267:707-726.
59. Vasmatzis G, Zhang C, Cornette JL, DeLisi C. Computational determination of side chain specificity for pockets in class I MHC molecules. Mol Immunol 1996;33:1231-1239.
60. Sezerman U, Vajda S, DeLisi C. Free energy mapping of class I MHC molecules and structural determination of bound peptides. Protein Sci 1996;5:1272-1281.
61. Takahashi H, et al. Structural requirements for class I MHC molecule-mediated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immunodeficiency virus envelope protein. J Exp Med 1989;170:2023-2035.
62. Gulukota K, Vajda S, DeLisi C. Peptide docking using dynamic programming. J Comput Chem 1996;17:418-428.
63. Stites WE, Pranata J. Empirical evaluation of the influence of side chains on the conformational entropy of the polypeptide backbone. Proteins 1995;22:132-140.
64. Madden DR, Garboczi DN, Wiley DC. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell 1993;75:693-708.
65. + CTL. Mol Immunol 1994;31:1285-1293.
66. + cytotoxic T lymphocytes by peptide and purified cell-free class I molecules. Int Immunol 1993;5:1129-1138.
67. Mayer MM. Complement and complement fixation. In: Kabat EA, ed. Experimental immunochemistry. Vol 2.0. Springfield, Illinois: Thomas; 1961. p.133-240.
68. Kageyama S, Tsomides TJ, Sykulev Y, Eisen HN. Variations in the number of peptide-MHC class I complexes required to activate cytotoxic T cell responses. J Immunol 1995;154:567-576.
69. + cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1995;92: 11990-11992.
70. Sykulev Y, Joo M, Vturina I, Tsomides TJ, Eisen HN. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 1996;4:565-571.
71. Matsui K, Boniface JJ, Reay PA, Schild H, Fazekas de St Groth B, Davis MM. Low affinity interaction of peptide-MHC complexes with T cell receptors. Science 1991;254:1788-1791.
72. Reay PA, Wettstein DA, Davis MM. pH dependence and exchange of high and low responder peptides binding to a class II MHC molecule. EMBO J 1992;11:2829-2839.
73. Margulies DH, Corr M, Boyd LF, Khilko SN. MHC class I/peptide interactions: binding specificity and kinetics. J Mol Recognit 1993;6:59-69.
74. Corr M, et al. T cell receptor-MHC class I peptide interactions: affinity, kinetics, and specificity. Science 1994;265:946-949.
75. k complexes: correlation of the dissociation rate with T-cell responsiveness. Proc Natl Acad Sci USA 1994;91: 12862-12866.
76. Sykulev Y, Brunmark A, Jackson M, Cohen RJ, Peterson PA, Eisen HN. Kinetics and affinity of reactions between an antigen-specific T cell receptor and peptide-MHC complexes. Immunity 1994;1:15-22.
77. Sykulev Y, et al. High-affinity reactions between antigen-specific T-cell receptors and peptides associated with allogeneic and syngeneic major histocompatibility complex class I proteins. Proc Natl Acad Sci USA 1994;91: 11487-11491.
78. Khilko SN, Jelonek MT, Corr M, Boyd LF, Bothwell AL, Margulies DH. Measuring interactions of MHC class I molecules using surface plasmon resonance. J Immunol Methods 1995;183:77-94.
79. Alam SM, et al. T-cell-receptor affinity and thymocyte positive selection. Nature 1996;381:616-620.
80. Lyons DS, et al. A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. Immunity 1996;5:53-61.
81. Kurepa Z, Forman J. Peptide binding to the class Ib molecule, Qa-1b. J Immunol 1997;158:3244-3251.
82. Smith JD, Lie WR, Gorka J, Myers NB, Hansen TH. Extensive peptide ligand exchange by surface class I major histocompatibility complex molecules independent of exogenous β2-microglobulin. Proc Natl Acad Sci USA 1992;89:7767-7771.
83. Ojcius DM, Abastado JP, Casrouge A, Mottez E, Cabanie L, Kourilsky P. Dissociation of the peptide-MHC class I complex limits the binding rate of exogenous peptide. J Immunol 1993;151:6020-6026.
84. Ojcius DM, Godeau F, Abastado JP, Casanova JL, Kourilsky P. Real-time measurement of antigenic peptide binding to empty and preloaded single-chain major histocompatibility complex class I molecules. Eur J Immunol 1993;23:1118-1124.
85. Ishioka GY, et al. Failure to demonstrate long-lived MHC saturation both in vitro and in vivo. Implications for therapeutic potential of MHC-blocking peptides. J Immunol 1994;152:4310-4319.
86. Kroon AIPMd, McConnell HM. Kinetics and specificity of peptide-MHC class II complex displacement reactions. J Immunol 1994;152:609-619.
87. Lanzavecchia A, Reid PA, Watts C. Irreversible association of peptides with class II MHC molecules in living cells. Nature 1992;357:249-252.
88. Gakamsky DM, Bjorkman PJ, Pecht I. Peptide interaction with a class I major histocompatibility complex-encoded molecule: allosteric control of the ternary complex stability. Biochemistry 1996;35:14841-14848.
89. Bergman RN, Hechter O. Neurohypophyseal hormone-responsive renal adenylate cyclase. IV. A random-hit matrix model for coupline in a hormone-sensitive adenylate cyclase system. J Biol Chem 1978;253:3238-3250.
90. DeLisi C. The magnitude of signal amplification by ligand-induced receptor clustering. Nature 1981;289:322-323.
91. Beeson C, et al. Early biochemical signals arise from low affinity TCR-ligand reactions at the cell-cell interface. J Exp Med 1996;184:777-782.
92. Rabinowitz JD, et al. Altered T cell receptor ligands trigger a subset of early T cell signals. Immunity 1996;5:125-135.
93. Rabinowitz JD, Beeson C, Lyons DS, Davis MM, McConnell HM. Kinetic discrimination in T-cell activation. Proc Natl Acad Sci USA 1996;93:1401-1405.
94. England RD, Kullberg MC, Cornette JL, Berzofsky JA. Molecular analysis of a heteroclitic T cell response to the immunodominant epitope of sperm whale myoglobin. Implications for peptide partial agonists. J Immunol 1995;155:4295-4306.
95. Lenardo MJ. Interleukin-2 programs mouse αβ T lymphocytes for apoptosis. Nature 1991;353:858-861.
96. Critchfield JM, et al. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 1994;263:1139-1143.
97. Critchfield JM, Zuniga-Pflucker JC, Lenardo MJ. Parameters controlling the programmed death of mature mouse T lymphocytes in high-dose suppression. Cell Immunol 1995;160:71-78.
98. Zheng L, et al. Mature T lymphocyte apoptosis in the healthy and diseased immune system. Adv Exp Med Biol 1996;406:229-239.
99. Hornung F, Zheng L, Lenardo MJ. Maintenance of clonotype specificity in CD95/Apo-1/Fas-mediated apoptosis of mature T lymphocytes. J Immunol 1997;159:3816-3822.
100. Reich Z, Boniface JJ, Lyons DS, Borochov N, Wachtel EJ, Davis MM. Ligand-specific oligomerization of T-cell receptor molecules. Nature 1997;387:617-620.
101. Rao A, Ko WW, Faas SJ, Cantor H. Binding of antigen in the absence of histocompatibility proteins by arsonate-reactive T-cell clones. Cell 1984;36:879-888.
102. Symer DE, Dintzis RZ, Diamond DJ, Dintzis HM. Inhibition or activation of human T cell receptor transfectants is controlled by defined, soluble antigen arrays. J Exp Med 1992;176:1421-1430.
103. Bell GI. Theoretical models for cell-cell interactions in immune responses. In: DeLisi C, Blumenthal R, eds. Physical chemistry aspects of cell surface events in cellular regulation. Vol 4. New York: Elsevier/North-Holland; 1979. p. 371-392.
104. Kane KP, Mescher MF. Activation of CD8-dependent cytotoxic T lymphocyte adhesion and degranulation by peptide class I antigen complexes. J Immunol 1993;150:4788-4797.
105. O'Rourke AM, Mescher MF. The roles of CD8 in cytotoxic T lymphocyte function. Immunol Today 1993;14:183-188.
106. O'Rourke AM, Ybarrondo B, Mescher MF. CD8 and antigen-specific T cell adhesion cascades. Semin Immunol 1993;5:263-270.
107. Garcia KC, et al. CD8 enhances formation of stable T-cell receptor/MHC class I molecule complexes. Nature 1996;384:577-581.
108. Janeway CA. The T cell receptor as a multicomponent signalling machine: CD4/CD8 coreceptors and CD45 in T cell activation. Annu Rev Immunol 1992;10:645-674.
109. Hampl J, Chien YH, Davis MM. CD4 augments the response of a T cell to agonist but not to antagonist ligands. Immunity 1997;7:379-385.